Gene Therapy, Open-label, Dose-escalation Study of SPK-9001 [Adeno-associated Viral Vector With Human Factor IX Gene] in Subjects With Hemophilia B

Trial Profile

Gene Therapy, Open-label, Dose-escalation Study of SPK-9001 [Adeno-associated Viral Vector With Human Factor IX Gene] in Subjects With Hemophilia B

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs AAV8-hFIX19 (Primary)
  • Indications Haemophilia B
  • Focus Adverse reactions
  • Sponsors Spark Therapeutics
  • Most Recent Events

    • 02 Aug 2017 According to a Spark Therapeutics media release, updated data from this study has been presented at International Society on Thrombosis and Haemostasis (ISTH) 2017 Congress.
    • 10 Jul 2017 Interim results published (n=10; June 5, 2017 data cut off) in a Spark Therapeutics media release.
    • 23 Jun 2017 According to a Spark Therapeutics media release, Updated interim data from this trial will be presented at the International Society on Thrombosis and Haemostasis (ISTH) 2017 Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top